Our study shows that patients receiving PD-1 inhibitors in combination with chemotherapy have better survival endpoints in advanced GC/GEJC, especially for patients with positive PD-L1 expression, in Asia, in men and under 65 years of age. Here, CD274 is linked to gastric cancer.